ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative melanoma-Reference-Cited by-同舟云学术

ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative melanoma

Published:2015-06-13 Issue:26 Volume:6 Page:22348-22360
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Hutchinson Katherine E.¹,Johnson Douglas B.²,Johnson Adam S.³,Sanchez Violeta²,Kuba Maria³,Lu Pengcheng⁴,Chen Xi⁴,Kelley Mark C.⁵,Wang Qingguo⁶,Zhao Zhongming¹⁶,Kris Mark⁷,Berger Michael F.⁸⁹,Sosman Jeffrey A.²,Pao William²¹⁰

Affiliation:

1. Department of Cancer Biology, Vanderbilt University Medical Center, Nashville, Tennessee, USA

2. Department of Medicine/Division of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, Tennessee, USA

3. Department of Pathology, Microbiology & Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA

4. Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, USA

5. Department of Surgery, Division of Surgical Oncology and Endocrine Surgery, Vanderbilt University Medical Center, Nashville, Tennessee, USA

6. Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee, USA

7. Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, USA

8. Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, USA

9. Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, USA

10. Currently an employee of Roche Pharma Research and Early Development, Basel, Switzerland

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancer;npj Precision Oncology;2023-01-26

2. Adaptive Resistance to Lorlatinib via EGFR Signaling in ALK-rearranged Lung Cancer;2022-10-05

3. The A to I editing landscape in melanoma and its relation to clinical outcome;RNA Biology;2022-08-21

4. Dual-specificity phosphatases: therapeutic targets in cancer therapy resistance;Journal of Cancer Research and Clinical Oncology;2022-01

5. Analysis of CRISPR‐Cas9 screens identifies genetic dependencies in melanoma;Pigment Cell & Melanoma Research;2020-09-07